000 01632 a2200457 4500
005 20250513132549.0
264 0 _c19980102
008 199801s 0 0 eng d
022 _a0008-543X
024 7 _a10.1002/(sici)1097-0142(19971215)80:12+<2583::aid-cncr34>3.3.co;2-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDeNardo, S J
245 0 0 _aImportance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
_h[electronic resource]
260 _bCancer
_cDec 1997
300 _a2583-90 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents, Phytogenic
_xtherapeutic use
650 0 4 _aBone Marrow
_xdrug effects
650 0 4 _aCombined Modality Therapy
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMammary Neoplasms, Experimental
_xtherapy
650 0 4 _aMice
650 0 4 _aMice, Inbred BALB C
650 0 4 _aMice, Nude
650 0 4 _aPaclitaxel
_xtherapeutic use
650 0 4 _aRadioimmunotherapy
650 0 4 _aTumor Cells, Cultured
650 0 4 _aWeight Loss
650 0 4 _aYttrium Radioisotopes
_xtherapeutic use
700 1 _aKroger, L A
700 1 _aLamborn, K R
700 1 _aMiers, L A
700 1 _aO'Donnell, R T
700 1 _aKukis, D L
700 1 _aRichman, C M
700 1 _aDeNardo, G L
773 0 _tCancer
_gvol. 80
_gno. 12 Suppl
_gp. 2583-90
856 4 0 _uhttps://doi.org/10.1002/(sici)1097-0142(19971215)80:12+<2583::aid-cncr34>3.3.co;2-8
_zAvailable from publisher's website
999 _c9376311
_d9376311